We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Indianapolis, IN based Eli Lilly and Company (LLY - Free Report) , boasts of a wide range of products that serve a vast number of therapeutic areas. The company focuses primarily on central nervous system disorders, metabolic diseases, autoimmune diseases, cardiovascular diseases and cancer, which are all high growth areas and represent significant commercial potential.
Lilly’s earnings performance has been mixed. Its earnings beat expectations in three of the last four quarters, with the average positive surprise being 1.20%.
Currently, Lilly has a Zacks Rank #2 (Buy), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Lilly beat fourth quarter earnings. The company reported EPS of $1.73 per share while our consensus called for EPS of $1.52.
Revenues Beat: Revenues beat expectations. Lilly posted revenues of $6.11 billion, compared to our consensus estimate of $6.07 billion.
2020 Outlook: Lilly re-affirmed its 2020 adjusted earnings guidance while slightly raised its revenue guidance.
Adjusted earnings are expected in the range of $6.70-$6.80 per share. Revenues are expected in a range of $23.7 billion-$24.2 billion compared to $23.6 billion-$24.1 billion previously.
The Zacks Consensus Estimate for earnings and revenues in 2020 is $6.77 per share and $23.93 billion, respectively.
Stock Price Impact: Shares were around 1.5% in pre-market trading.
Check back later for our full write up on this Lilly earnings report later!
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Eli Lilly (LLY) Tops Q4 Earnings & Sales, Keeps 2020 View
Indianapolis, IN based Eli Lilly and Company (LLY - Free Report) , boasts of a wide range of products that serve a vast number of therapeutic areas. The company focuses primarily on central nervous system disorders, metabolic diseases, autoimmune diseases, cardiovascular diseases and cancer, which are all high growth areas and represent significant commercial potential.
Lilly’s earnings performance has been mixed. Its earnings beat expectations in three of the last four quarters, with the average positive surprise being 1.20%.
Currently, Lilly has a Zacks Rank #2 (Buy), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Lilly beat fourth quarter earnings. The company reported EPS of $1.73 per share while our consensus called for EPS of $1.52.
Revenues Beat: Revenues beat expectations. Lilly posted revenues of $6.11 billion, compared to our consensus estimate of $6.07 billion.
2020 Outlook: Lilly re-affirmed its 2020 adjusted earnings guidance while slightly raised its revenue guidance.
Adjusted earnings are expected in the range of $6.70-$6.80 per share. Revenues are expected in a range of $23.7 billion-$24.2 billion compared to $23.6 billion-$24.1 billion previously.
The Zacks Consensus Estimate for earnings and revenues in 2020 is $6.77 per share and $23.93 billion, respectively.
Stock Price Impact: Shares were around 1.5% in pre-market trading.
Check back later for our full write up on this Lilly earnings report later!
Eli Lilly and Company Price and Consensus
Eli Lilly and Company price-consensus-chart | Eli Lilly and Company Quote
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>